Skip to main content
ORGO logo

ORGO · Organogenesis Holdings Inc.

Track ORGO — free
$0.81 +0.02 (+2.33%)
Market Cap
$102.44M
Shares
129.80M
Volume · Nov 20 222.25K Avg daily vol (3M) 845.21K

Price & Indicators

 

Key stats

Close
$0.79
Thu 19 Nov
Open
$0.84
Thu 19 Nov
Average volume, 30 days
1.0M
shares a session
Short interest
15.6M
12.0% of shares · 14.0 days to cover
Day range
$0.78$0.85
Open $0.84 Close $0.79
52-week closing range
$0.76$5.87
Close $0.79 86.6% under the high
Short volume, last session
69%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 5
Earnings call
Third-Quarter Net Product Revenue Down 70%; MNUVIX Review Extended

Third-quarter net product revenue was $45.5 million, down 70% year-over-year. Full-year 2026 total net revenue is now expected at $179 million to $200 million, a decline of 65% to 68%. The FDA will extend the MNUVIX PDUFA target date from April 24, 2027, after identifying 18 items requiring remediation at the Norwood facility.

4 source passages
Net product revenue was $45.5 million, down 70%. We now expect total net revenue for the full year of 2026 of $179 million to $200 million, representing a decline in the range of 65% to 68% year-over-year the PDUFA target date will be extended from April 24, 2027. During the third quarter, the FDA completed a pre-licensed inspection of our Norwood facility and identified 18 items requiring remediation. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue fell (63%); nine-month net loss totaled $179.1 million

Organogenesis reported a $179.1 million net loss for the nine months ended September 30, 2026, while net product revenue fell (63%) amid clinician confusion and market disruption following CMS’s December 2025 comments on discarded product.

Revenue $45.46M ▼ 69.9% Net loss $29.63M Diluted EPS -$0.25
Read from the MD&A section
4 source passages
Organogenesis is a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of product solutions for the advanced wound care and surgical and sports medicine markets. During the nine months ended September 30, 2026, net cash used in operating activities was $29.1 million, resulting from our net loss of $179.1 million, partially offset by net cash provided in connection with changes in our operating assets and liabilities of $71.5 million, and non-cash charges of $78.4 million. Net product revenue | 124,512 | 337,959 | (213,447) | | (63%) The decrease in net product revenue in the three and nine months ended September 30, 2026 was primarily due to a decrease in Advanced Wound Care net product revenue attributed to continued clinician confusion and material disruption in the market following the withdrawal of the LCD coverage policies for skin substitutes and CMS published comments regarding discarded product in December 2025. Open the document at this passage
Nov 5
Current report 8-K
Revenue falls 70%, net loss reaches $29.6 million

Organogenesis Holdings Inc. reported revenue of $45.5 million, down 70%, and a net loss of $29.6 million. Cash was $26.9 million with no debt at September 30, 2026; 2026 revenue guidance is $179.4 million to $200.0 million.

Financial results
5 source passages
Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results Net product revenue for the third quarter of 2026 was $45.5 million, compared to $150.5 million for the third quarter of 2025, a decrease of $105.0 million, or 70%. Net loss for the third quarter of 2026 was $29.6 million, or $(0.25) per share, compared to net income of $21.6 million, or $0.11 per share for the third quarter of 2025, an increase in net loss of $51.2 million, or $(0.36) per share. As of September 30, 2026, the Company had $26.9 million in cash, cash equivalents and restricted cash and no outstanding debt obligations, compared to $94.3 million in cash, cash equivalents and restricted cash and no outstanding debt obligations as of December 31, 2025. Total net revenue between $179.4 million and $200.0 million, representing a decline in the range of 65% to 68%, as compared to total net revenue of $564.2 million for the year ended December 31, 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$352.05M
Trailing 12 months
Net income (TTM)
−$135.35M
Trailing 12 months
Revenue growth YoY
-69.9%
Year over year
Operating margin
-24.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-0.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.4%
Year over year · fewer shares
Price change (1Y)
-84.6%
Trailing year
Short interest
12.0%
Latest settlement · 14.0 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Q3 revenue increased 6% sequentially, claims analysis indicates market-share gains, operating expenses fell 42%, management expects positive adjusted EBITDA in the fourth quarter, and the FDA accepted the Mnuvix BLA for review. However, net product revenue and gross margin fell sharply year over year, operating, net and adjusted EBITDA results deteriorated, cash declined to $26.9 million, guidance reflects a more measured recovery, low-cost inventory is delaying recovery, and Mnuvix faces remediation requirements, a delayed timeline and added cost.

Bullish
  • + Q3 revenue increased 6% sequentially as growth trends improved. new
  • + Claims analysis indicates market share increased more than 30% versus Q1. new
  • + The PREPARE trial achieved its primary endpoints and showed statistically significant wound-closure improvements at 12 weeks. new
  • + Q3 operating expenses declined 42% year over year. new
  • + Management expects positive adjusted EBITDA generation in the fourth quarter. new
  • + The FDA accepted the Mnuvix BLA for review. new
Bearish
  • − Q3 net product revenue declined 70% year over year and gross margin fell to 52% from 76%. new
  • − Updated full-year guidance reflects a more measured revenue recovery. new
  • − Excess low-cost inventory from exiting competitors is delaying the skin-substitute market recovery. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −63%
below
Price vs 50-day avg −30%
below
RSI (14) 38
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −23%
trailing
6-month return −67%
trailing
YTD return −85%
this year
Relative strength −61%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +20 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.03% of shares out · ▲ +0.2% MoM · 14.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
123 holders — mid 3-yr range
Squeeze score 63
elevated · 0–100
Fundamentals
Strong
Revenue growth +17%
Y/Y
Gross margin 65%
contracting
EPS growth +1600%
Y/Y
Free cash flow $-24.5M
Quant / Vol
risk profile
Very High
Volatility 68%
annualized · 1-yr
Max drawdown −87%
past year
ATR 11.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 3
Latest guidance · from the Earnings Call filed Nov 5, 2026
full year of 2026
Total net revenue $179M – $200M
prior FY $564.17M midpoint −66.4% Y/Y
Sales of advanced wound care products Lowered $151M – $171M
Aug 6, 2026 $151M – $183M changed to Nov 5, 2026 $151M – $171M
Sales of our surgical and sports medicine products Lowered $26M – $27M
Aug 6, 2026 $26M – $30M changed to Nov 5, 2026 $26M – $27M
Grant income Maintained $1.9M
Aug 6, 2026 $1.9M changed to Nov 5, 2026 $1.9M
remediation expected to be done by September 30, 2027
Total cost for the remediation $8M
Incremental cost $4M
2026
Share of remediation spend done in 2026 25%
Previous outlook earlier release · from the 8-K filed Aug 6, 2026

Still-open targets the latest release did not restate under the same label.

Total net revenue · For the year ending December 31, 2026 $179M – $215M
Guided vs delivered · last 3 settled
Net revenue year ending December 31, 2023
guided $433M – $446M
$433.14M In line
Net revenue For the year ending December 31, 2022
guided $448M – $465M
$450.89M In line
Net revenue 12 months ended December 31, 2021
guided $458M – $470M
$467.36M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−63% Bearish
Price vs 50-day avg
−30% Bearish
RSI (14)
38 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +20 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.03% of shares out · ▲ +0.2% MoM · 14.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
123 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 1% Range high $6
vs 200-day avg -63% vs 50-day avg -30%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted net income (loss) non-GAAP -162.07M Nine Months Ended September 30, 2026 —
Non-GAAP operating income (loss) non-GAAP -126.11M Nine Months Ended September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ORGO
Organogenesis Holdings Inc.
this stock
$102.44M -84.8% +17.0% — 12.0%
TAK
Takeda Pharmaceutical Co Ltd
$68.40B +37.3% — — 0.1%
GALDY
Galderma Group AG
$50.89B +5.3% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$44.97B +23.5% +4.3% 87.6 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
123
% held
50.8%
Net QoQ
-97.1K sh
Top holder
MORGAN STANLEY
Held Float
View
Held by Funds
Fund positions
150
View
Short & Settlement
Short Interest Rising
Shares short
15.6M
Days to cover
14.0d
Change
+24.0K sh
View
Short Volume
Short vol %
69%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
430
Value
$387
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
54.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$564.2M
Net income (FY)
$37.0M
EPS diluted
$0.15
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 5, 2026
This year
13

Organogenesis Holdings Inc. reported revenue of $45.5 million, down 70%, and a net loss of $29.6 million. Cash was $26.9 million with no debt at September 30, 2026; 2026 revenue guidance is $179.4 million to $200.0 million.

View
Proposed Sales
Value
$1.0M
Shares
200.0K
Filed
Dec 16, 2025
View
Exempt Offerings
Offering
$130.0M
Filed
Nov 27, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Organogenesis Holdings Inc. Repor…
Published
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
ORGO -18.2% -23.4% -66.6% +2.8% -84.8%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -12.8% -17.1% -60.9% +8.0% -89.7%
Key facts CIK 1661181 CUSIP 68621F102 13F (30d) 128 filings 112 filers Visit website Investor relations